What Patients With Multiple Myeloma Should Know About Blenrep-Linked Vision Problems and Their Legal Rights

FDA Raises Alarms About Eye Safety in Blenrep Cancer Drug Combination

The U.S. Food and Drug Administration (FDA) has flagged serious eye safety concerns related to Blenrep (belantamab mafodotin), a blood cancer drug developed by GSK, especially when used in combination with other therapies for multiple myeloma. According to the agency, new data suggests the potential for unique ocular toxicity—including blurred vision, light sensitivity, and dry eye—that raises questions about the drug’s safety profile. These risks are now under formal review as GSK seeks broader approval for Blenrep alongside established cancer drugs like bortezomib, pomalidomide, and the steroid dexamethasone.

Blenrep was initially approved under the FDA’s accelerated approval program in 2020 based on early signs of efficacy. However, serious concerns have remained about eye damage. With new trial results now under consideration, the agency is scrutinizing not only whether Blenrep is effective but whether the benefit outweighs the risk—particularly for eye-related side effects that may not be manageable in normal healthcare settings.

What Is Blenrep and How Is It Supposed to Work?

Blenrep is part of a newer class of drugs called antibody-drug conjugates (ADCs). These targeted therapies are designed to attach to cancer cells and deliver toxic agents directly to the tumor, ideally sparing healthy tissue. The drug specifically targets BCMA (B-cell maturation antigen), a protein found on myeloma cells. Once attached, the drug releases a chemical that kills the cancer cells.

When it works as intended, Blenrep offers a more targeted alternative to traditional chemotherapy. But the effectiveness of the treatment does not erase the drug’s risk profile. A number of patients in trials have experienced moderate to severe ocular toxicity. These effects are considered serious because they may lead to lasting vision damage.

FDA Concerned About Reproducibility of Safety Measures

A major concern raised by FDA reviewers involves how eye health was monitored during clinical trials. In tightly controlled studies, patients underwent routine eye exams and dosage adjustments based on the severity of side effects. However, the FDA notes that such careful protocols may not be feasible in general clinical settings.

In real-world medical practice, not all oncology clinics have immediate access to eye specialists or the capacity to conduct regular vision assessments. This makes it difficult to manage side effects consistently, potentially exposing more patients to preventable vision damage. Additionally, questions remain about whether GSK has established a universally safe dosage for Blenrep in combination with other drugs.

Ocular Toxicity: What Are the Risks to Patients?

FDA reviewers describe the vision issues associated with Blenrep as a “unique toxicity” not seen with other treatments for multiple myeloma. The ocular complications reported include:

  • Blurred vision
  • Photophobia (light sensitivity)
  • Dry eye
  • Corneal ulcers or abrasions
  • Eye pain

These conditions are not only painful and disruptive but can also lead to long-term or permanent impairment. Some patients may require corrective surgery or prolonged medical treatment. The inability to predict which patients will develop eye damage makes these side effects even more concerning.

Although patients enrolled in the trials had access to comprehensive eye care, individuals receiving the drug in everyday practice may not have the same support, leading to delayed recognition and treatment of side effects.

Legal Liability and Patient Rights: When a Drug Causes Harm

When a drug poses known risks that are not adequately disclosed or mitigated, affected patients may be entitled to financial compensation. Drug manufacturers are responsible for conducting thorough safety testing, communicating all known side effects, and ensuring that medical professionals can reasonably manage risks in normal practice settings.

If GSK failed to ensure that Blenrep’s safety protocols could be reproduced outside of a clinical trial environment, or if they pushed for approval without full disclosure of long-term eye risks, they could face liability in future lawsuits.

Potential legal claims may include:

  • Product liability
  • Failure to warn
  • Negligence in clinical trial design or implementation
  • Negligence in dosage recommendations

Patients who have experienced permanent or severe eye injuries after being treated with Blenrep should consider a legal review of their case.

What Patients Should Do If They Experience Eye Problems After Blenrep

If you or a loved one is being treated with Blenrep and you begin experiencing vision problems, it is essential to take the following steps:

  1. Notify your oncologist immediately and request a referral to an ophthalmologist.
  2. Document all symptoms, dates, and any medical visits related to your eye health.
  3. Request a copy of your treatment plan, including dosage levels and combination therapies.
  4. Save packaging or prescription documentation if you are self-administering at home.
  5. Consult a personal injury attorney who has experience with pharmaceutical litigation.

Acting quickly can improve your chances of identifying the cause of your symptoms and strengthening any legal claim you may have.

Contact Parker Waichman LLP For A Free Case Review

If you have suffered eye injuries after being treated with Blenrep for multiple myeloma, you may be entitled to financial compensation. Parker Waichman LLP is a national personal injury law firm that handles pharmaceutical injury claims and is currently reviewing cases related to Blenrep. Our legal team is ready to assess your case at no cost.

Call 1-800-YOUR-LAWYER (1-800-968-7529) for a free consultation today. You may have a limited time to file a claim, so don’t delay. Regardless of your location or where your injury occurred, our nationwide product injury law firmis ready to assist you and discuss your claim for free.

SHARE:
Free Consultation

Parker Waichman LLP

Untitled(Required)

Parker Waichman Reviews

4.8 from 549 Reviews

Related Testimonials

Our law firm is ready to represent you in your injury case. We’ve helped many New York residents as well as those needing help nationwide. Contact our team for a free case consultation today.

We Have Many Locations To Serve You
Serving Mass Tort Clients Nationally

We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.

Long Island - Nassau

Parker Waichman LLP

6 Harbor Park Drive

Port Washington, NY 11050

(516) 466-6500

Long Island – Suffolk

Parker Waichman LLP

201 Old Country Road – Suite 145

Melville, NY 11747

(631) 390-0800

New York City

Parker Waichman LLP

59 Maiden Lane, 6th Floor

New York, NY 10038

(212) 267-6700

Queens

Parker Waichman LLP

118-35 Queens Boulevard, Suite 400

Forest Hills, NY 11375

(718) 469-6900

Brooklyn

Parker Waichman LLP

300 Cadman Plaza West

One Pierrepont Plaza, 12th Floor

Brooklyn, NY 11201

(718) 554-8055

Florida

Parker Waichman LLP

27299 Riverview Center Boulevard, Suite 108

Bonita Springs, FL 34134

(239) 390-1000

New Jersey

Parker Waichman LLP

80 Main Street, Suite 265

West Orange, NJ 07052

(973) 323-3603
Nationwide Service

We handle mass torts cases nationwide. Please contact our office to learn more.